中国药物经济学2025，Vol.20Issue(7)：13-18,6.DOI:10.12010/j.issn.1673-5846.2025.07.002
华蟾素注射液治疗原发性肝癌的临床综合评价
Clinical Comprehensive Evaluation of Cinbufosin Injection in the Treatment of Primary Hepatic Carcinoma
摘要
Abstract
Objective To evaluate the comprehensive clinical value of cefadin injection in the treatment of primary liver cancer.Methods Based on evidence-based pharmacy,pharmacoeconomics,health technology evaluation and other methodologies,relevant literature data,public data,questionnaires and other data,the Guidelines for the Management of Comprehensive Clinical Evaluation of Pharmaceutical Products(2021)and the standard for Clinical Comprehensive Evaluation Report of proprietary Chinese Medicines were used.The effectiveness,safety,economy,innovation,suitability and accessibility of Hualbufosin injection in the treatment of primary liver cancer were evaluated comprehensively.Results In terms of effectiveness,huadin injection has a good effect in improving the clinical effective rate and quality of life of patients with primary liver cancer,prolonging their survival period,and reducing alpha-fetoprotein(AFP).In terms of safety,there are relatively few serious adverse reactions.In terms of economy,it has certain cost-effectiveness advantages.In terms of innovation,18 Chinese patents have been approved,and the related technologies are classified as state secrets.In terms of suitability,this drug is an injectable preparation,with relatively narrow application scenarios and reduced patient compliance with its use.In terms of accessibility,it is available for sale in medical institutions across 31 provinces,municipalities and autonomous regions in China,with good supply accessibility.Conclusion Cinbufosin injection has certain clinical value in the treatment of primary hepatic carcinoma,which can provide reference for drug selection and clinical use in medical institutions.关键词
华蟾素注射液/原发性肝癌/临床综合评价Key words
Cinbufosin injection/Primary hepatic carcinoma/Clinical comprehensive evaluation分类
医药卫生引用本文复制引用
劳传玲,黄光明..华蟾素注射液治疗原发性肝癌的临床综合评价[J].中国药物经济学,2025,20(7):13-18,6.基金项目
广西中医药管理局项目(GXZYA20230250) （GXZYA20230250）
